Skip to main content

Table 1 Main characteristics of randomized controlled trials (RCT) on the use of GnRH in luteal phase

From: Administration of single-dose GnRH agonist in the luteal phase in ICSI cycles: a meta-analysis

Trial Randomization Protocol stimulation Luteal Phase Results
    Study group
GnRH-a
Control group Others medicines
(all patients)
 
Tesarik et al., 2006 [18] Embryo transfer day
Computer generated list
Opaque envelopes
Blinding
GnRH-a long protocol/GnRH-ant multiple dose
+
r-FSH/HMG
+
r-HCG
n:150 GnRH-a long protocol)
n:150 GnRH-ant protocol
Single injection
Dose:0.1 mg/triptorelin
Day 6 after ICSI
n:150
(GnRHa-long protocol)
n:150
(Antagonist protocol)
Placebo
E2 valerate (4 mg)
+
Vaginal micronized progesterone(400 mg) +
r-HCG (single dose)
Improvement implantation/live birth rates
Ata et al., 2008 [24] Embryo transfer day
Computer generated list
Opaque envelopes
Blinding
GnRH-a long protocol
+
r-FSH
+
HCG
n:285
Single injection
Dose:0.1 mg/triptorelin
Day 6 after ICSI
n:285
Placebo
Vaginal progesterone gel/90 mg No differences
Isik et al., 2009 [15] Embryo transfer day
Computer generated list
Blinding
GnRH-ant multiple dose +
r-FSH/HMG
+
hCG/r-hCG
n:74
Single injection
Dose:0.5 mg/leuprolide
Day 6 after ICSI
n:80
No placebo
Vaginal micronized progesterone(600 mg) +
HCG(single dose)
Improvement implantation/clinical pregnancy rates
Razieh et al., 2009 [16] Drawing piece of paper from a bag GnRH-a long protocol
+
r-FSH
+
HCG
n:90
Single injection
Dose:0.1 mg/triptorelin
Day 5/6 after ICSI
n:90
Placebo
Vaginal micronized progesterone(800 mg) Improvement implantation/clinical pregnancy rates
Ata and Urman, 2010 [23] Embryo transfer day
Computer generated list
Opaque envelopes
Blinding
GnRH-ant multiple dose +
r-FSH/HMG
+
r-HCG
n:38
Single injection
Dose:0.1 mg/triptorelin
Day 6 after ICSI
n:52
Placebo
Vaginal progesterone gel/90 mg Lower Implantation/ongoing pregnancy rates